R2 Dermatology Announces Signing of Exclusive Asia-Pacific Distribution Agreement with China’s Huadong Medicine Company Lim...
June 13 2019 - 8:30AM
R2 Dermatology (“R2”) announced today that it has entered into an
exclusive distribution agreement with China’s Huadong Medicine
Company Limited (“Huadong”) for the Asia-Pacific Region. In
exchange, Huadong will make an equity investment in R2 Dermatology
to fund R2’s next phase of product and market development.
“We are delighted to have found a superb strategic partner in
Huadong and particularly excited to work with their entire team to
enter the Asia-Pacific Region, the most robust market in the world
for our portfolio of cold-based treatments for both aesthetically
lightening the normal pigmentation of the skin and the reduction
and elimination of hyperpigmentation of specific problem areas of
the skin due to aging, sun damage, and/or genetics,” said Gordie
Nye, Chief Executive Officer of R2.
R2 Dermatology was founded in late 2014 by Pansend Life Sciences
(a subsidiary of HC2 Holdings, Inc.) and Blossom Innovations.
Since inception, R2 has generated substantial safety
and efficacy studies in several multi-center clinical studies both
in North America and Asia. In addition, R2 has received two
US FDA 510(k) clearances for its clinical stage devices. Powered by
licensed IP from Blossom Innovations and Massachusetts General
Hospital, R2’s platform will provide a unique patient experience:
safe, comfortable treatments with no downtime and predictable,
efficacious outcomes.
“Our scientific founders from MGH -- Drs. Rox Anderson, Dieter
Manstein, and Henry Chan -- are among the most admired innovators
in the world of aesthetic dermatology. We can’t wait to
deliver another game-changing treatment of theirs to the market,”
said Mr. Nye.
Solebury-Trout served as investor relations advisor to R2
Dermatology in conjunction with this transaction.About R2
Dermatology
R2 Dermatology is a portfolio company within
Pansend Life Sciences, Ltd., a subsidiary of HC2 Holdings, Inc.
Located in San Ramon, California and founded in late 2014, R2
Dermatology is developing medical devices for the treatment of
aesthetic and medical skin conditions, including a skin lightening
and skin-tone evening product utilizing “cold technology”. R2
Dermatology has received market clearance from the U.S. Food and
Drug Administration for its second generation device, the R2 Dermal
Cooling System, a cryosurgical instrument intended for use in
dermatologic procedures for the removal of benign lesions of the
skin, based on exclusive licensing rights to a novel technology
invented by Blossom Innovations and Massachusetts General Hospital,
teaching affiliate of Harvard Medical School. Learn more
about R2 Dermatology at www.r2derm.com.
Contact
Ragan ReppondR2 Dermatology(925) 378-4400
HC2 (NYSE:HCHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
HC2 (NYSE:HCHC)
Historical Stock Chart
From Apr 2023 to Apr 2024